1.  To understand the challenges in performing genome-wide studies to identify genetic markers associated with chemotherapeutic toxicities.

2.  To understand both modifiable risk factors associated with cisplatin-induced ototoxicity and peripheral neuropathy.

3.  To understand the lack of diversity in pharmacogenomic studies and its impact on health outcomes.

Session date: 
07/12/2018 - 8:00am to 9:00am CDT
Evanston, IL 60201
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Eileen Dolan, PhD